Gedea Biotech secures €1.3 million
Gedea Biotech secures €1.3 million (14 MSEK) to advance its antibiotic-free vaginal infection treatment pHyph towards market launch. Gedea Biotech, part of LU Holding’s portfolio, announced in May that it has raised €1.3 million (14 MSEK) for additional development activities of their product pHyph for antibiotic-free treatment of vaginal infections. The funds will be used for: • An ongoing proof-
https://www.innovation.lu.se/en/article/gedea-biotech-secures-eu13-million - 2025-11-23
